• Liquidia swung to GAAP net income of $74.7 million, or $0.84 per basic share and $0.74 per diluted share.
• Net product sales rose to $170.4 million, driven by higher YUTREPIA volume; service revenue slipped to $1.3 million.
• Non-GAAP adjusted EBITDA climbed to $96.3 million, marking a fourth straight quarter of improving profitability.
• Cash and cash equivalents increased to $284.2 million; YUTREPIA logged about 5,900 unique prescriptions since June 2025 launch.
• CEO Roger Jeffs cited sustained adoption, with about 5,000 patients started; Liquidia activated sites and began enrollment for L606’s Re-Spire study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Liquidia Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608120630PRIMZONEFULLFEED9808267) on August 12, 2026, and is solely responsible for the information contained therein.